| abstract |
Summary bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease Pediatric dosage forms are provided herein for use in the treatment of a pediatric cholestatic liver disease by non-systematically administering to a subject, in need thereof, a therapeutically effective amount. a pediatric dosage form comprising an apical sodium-dependent bile acid transport inhibitor (asbti) or a pharmaceutically acceptable salt thereof. Pediatric dosage forms are also provided for use in the treatment of a pediatric liver disease, for use in decreasing serum bile acid or hepatic bile acid levels, for use in the treatment of pruritus, for use in reduction. liver enzymes or bilirubin comprising administering, non-systematically, to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an asbti or a pharmaceutically acceptable salt thereof. |